Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection
Julie Dyall,Christopher M. Coleman,Brit J. Hart,Thiagarajan Venkataraman,Michael R. Holbrook,Jason Kindrachuk,Reed F. Johnson,Gene G. Olinger,Peter B. Jahrling,Monique Laidlaw,Lisa M. Johansen,Calli M. Lear-Rooney,Pamela J. Glass,Lisa E. Hensley,Matthew B. Frieman +14 more
TLDR
The drugs identified in these screens provide new targets for in vivo studies as well as incorporation into ongoing clinical studies, and repurposing of existing drugs is likely the only solution for outbreaks due to emerging viruses.Abstract:
Outbreaks of emerging infections present health professionals with the unique challenge of trying to select appropriate pharmacologic treatments in the clinic with little time available for drug testing and development. Typically, clinicians are left with general supportive care and often untested convalescent-phase plasma as available treatment options. Repurposing of approved pharmaceutical drugs for new indications presents an attractive alternative to clinicians, researchers, public health agencies, drug developers, and funding agencies. Given the development times and manufacturing requirements for new products, repurposing of existing drugs is likely the only solution for outbreaks due to emerging viruses. In the studies described here, a library of 290 compounds was screened for antiviral activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV). Selection of compounds for inclusion in the library was dependent on current or previous FDA approval or advanced clinical development. Some drugs that had a well-defined cellular pathway as target were included. In total, 27 compounds with activity against both MERS-CoV and SARS-CoV were identified. The compounds belong to 13 different classes of pharmaceuticals, including inhibitors of estrogen receptors used for cancer treatment and inhibitors of dopamine receptor used as antipsychotics. The drugs identified in these screens provide new targets for in vivo studies as well as incorporation into ongoing clinical studies.read more
Citations
More filters
Journal ArticleDOI
Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods.
Canrong Wu,Yang Liu,Yueying Yang,Peng Zhang,Wu Zhong,Yali Wang,Qiqi Wang,Yang Xu,Mingxue Li,Xing-Zhou Li,Mengzhu Zheng,Lixia Chen,Hua Li,Hua Li +13 more
TL;DR: This study systematically analyzed all the proteins encoded by SARS-CoV-2 genes, compared them with proteins from other coronaviruses, predicted their structures, and built 19 structures that could be done by homology modeling and constructed a database of 78 commonly used anti-viral drugs.
Journal ArticleDOI
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
Guangdi Li,Erik De Clercq +1 more
TL;DR: The potential for repurposing existing antiviral agents to treat 2019-nCoV infection (now known as COVID-19) is discussed, some of which are already moving into clinical trials.
Journal ArticleDOI
Coronaviruses - drug discovery and therapeutic options.
TL;DR: The epidemiology, virology, clinical features and current treatment strategies of SARS and MERS are summarized, and the discovery and development of new virus-based and host-based therapeutic options for CoV infections are discussed.
Journal ArticleDOI
Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
Yadi Zhou,Yuan Hou,Jiayu Shen,Yin Huang,William R. Martin,Feixiong Cheng,Feixiong Cheng,Feixiong Cheng +7 more
TL;DR: This study presents an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV–host interactome and drug targets in the human protein–protein interaction network.
Journal ArticleDOI
Middle East respiratory syndrome.
TL;DR: The Middle East respiratory syndrome coronavirus (MERS-CoV) is a lethal zoonotic pathogen that was first identified in humans in Saudi Arabia and Jordan in 2012.
References
More filters
Journal ArticleDOI
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Ali Moh Zaki,Sander van Boheemen,Theo M. Bestebroer,Albert D. M. E. Osterhaus,Ron A. M. Fouchier +4 more
TL;DR: The clinical picture was remarkably similar to that of the severe acute respiratory syndrome (SARS) outbreak in 2003 and reminds us that animal coronaviruses can cause severe disease in humans.
Journal ArticleDOI
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
Piyush Gupta,Piyush Gupta,Tamer T. Onder,Guozhi Jiang,Guozhi Jiang,Kai Tao,Charlotte Kuperwasser,Robert A. Weinberg,Eric S. Lander +8 more
TL;DR: Global gene expression analyses show that salinomycin treatment results in the loss of expression of breast CSC genes previously identified by analyses of breast tissues isolated directly from patients, demonstrating the ability to identify agents with specific toxicity for epithelial CSCs.
Journal ArticleDOI
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
V. Stalin Raj,Huihui Mou,Saskia L. Smits,Dick H. W. Dekkers,Marcel A. Müller,Ronald Dijkman,Doreen Muth,Jeroen Demmers,Ali Moh Zaki,Ron A. M. Fouchier,Volker Thiel,Volker Thiel,Christian Drosten,Peter J. M. Rottier,Albert D. M. E. Osterhaus,Berend Jan Bosch,Bart L. Haagmans +16 more
TL;DR: Dipeptidyl peptidase 4 (DPP4; also known as CD26) is identified as a functional receptor for hCoV-EMC and will contribute critically to the understanding of the pathogenesis and epidemiology of this emerging human coronavirus, and may facilitate the development of intervention strategies.
Journal ArticleDOI
Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group.
Raoul J. de Groot,Susan C. Baker,Ralph S. Baric,Caroline Brown,Christian Drosten,Luis Enjuanes,Ron A. M. Fouchier,Monica Galiano,Alexander E. Gorbalenya,Ziad A. Memish,Stanley Perlman,Leo L.M. Poon,Eric J. Snijder,Gwen Stephens,Patrick C. Y. Woo,Ali Moh Zaki,Maria Zambon,John Ziebuhr +17 more
TL;DR: During the summer of 2012, in Jeddah, Saudi Arabia, a hitherto unknown coronavirus was isolated from the sputum of a patient with acute pneumonia and renal failure and was provisionally called human coronav virus Erasmus Medical Center (EMC).
Journal ArticleDOI
Synergistic drug combinations tend to improve therapeutically relevant selectivity.
Joseph Lehar,Andrew S Krueger,William Avery,Adrian Heilbut,Lisa M. Johansen,E. Roydon Price,Richard Rickles,Glenn F. Short,Jane Staunton,Xiaowei Jin,Margaret S. Lee,Grant R. Zimmermann,Alexis Borisy +12 more
TL;DR: Evidence is provided that synergistic drug combinations are generally more specific to particular cellular contexts than are single agent activities, and six combinations whose selective synergy depends on multitarget drug activity are highlighted.
Related Papers (5)
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou,Xing-Lou Yang,Xian Guang Wang,Ben Hu,Lei Zhang,Wei Zhang,Hao Rui Si,Yan Zhu,Bei Li,Chao Lin Huang,Hui-Dong Chen,Jing Chen,Yun Luo,Hua Guo,Ren Di Jiang,Meiqin Liu,Ying Chen,Xu Rui Shen,Xi Wang,Xiao Shuang Zheng,Kai Zhao,Quanjiao Chen,Fei Deng,Lin Lin Liu,Bing Yan,Fa Xian Zhan,Yan-Yi Wang,Gengfu Xiao,Zhengli Shi +28 more